Pfizer Inc. Q4 FY2025 earnings call

• 2025 was a strong year with Pfizer exceeding revenue and adjusted diluted EPS expectations, returning $9.8 billion to shareholders via dividends.
• Strategic acquisitions like Seagen, Metsera, and Biohaven have transformative potential. Progress in integrating Seagen products and advancing R&D programs, including FDA approval for PADCEV.
• Positive results from the VSPERT three study in obesity, demonstrating robust weight loss and favorable safety profile for the ultra-long-acting GLP-1 receptor agonist. Plans to advance over 20 obesity trials in 2026.
• Scaling AI across R&D, manufacturing, commercial, and patient engagement to improve productivity and innovation, with plans to expand to over 1,200 GPUs in the next two years.
• Prioritization of R&D programs, with expected progress in ~20 pivotal studies in 2026, including 10 in the Metsera portfolio and studies for elbrexvio and Lyme disease vaccine candidate.

For full year 2025, Pfizer Inc. recorded revenues of $62.6 billion, with operational revenue growth excluding COVID-19 products at 6%. Recently launched and acquired products delivered $10.2 billion in revenues for 2025, growing approximately 14% operationally. In the fourth quarter, revenues were $17.6 billion, with non-COVID products growing 9% operationally while COVID products declined ~40%. Full year 2025 adjusted gross margins expanded to 76%, and the fourth quarter adjusted gross margin was approximately 71%.

• Full year 2026 revenues expected in the range of $59.5 billion to $62.5 billion, and adjusted diluted EPS in the range of $2.80 to $3.00.
• COVID products expected to be ~$5 billion in 2026. Non-COVID product portfolio stable with ~$1.5 billion revenue compression due to generics.
• Non-COVID and LOE excluded revenues expected to grow approximately 4% operationally year-over-year.

Q: Can you elaborate on the tolerability seen in the VSPER III data and the role of 3944 in the market?

A: Chris Boshoff discussed tolerability distribution across weekly and monthly doses, no unexpected discontinuations, and Aamir Malik and Alexandre de Germay spoke about the commercial potential with efficacy, monthly dosing, and market willingness to pay out-of-pocket.

Q: How is the integration of Seagen going and its impact on oncology leadership?

A: Chris Boshoff mentioned successful integration with vibrant teams in Seattle, acceleration of programs like PADCEV and 4404, and positive preclinical and clinical data for oncology assets.

Q: What are metrics for AI investment and its return?

A: Chris Boshoff, Aamir Malik, and Alexandre de Germay discussed AI use in R&D (productivity, speed, cost), commercial (field force productivity, MROI), and enabling functions (automation of routine transactions) to drive productivity and ROI.